NeurologyLive

NeurologyLive™ provides both print and digital media resources tailored for healthcare professionals focused on treating neurological disorders. It delivers vital news and insights straight from leading medical conferences and experts in the field. This platform offers a comprehensive overview of the numerous new treatments being developed, showcasing their innovative mechanisms of action. As the need for neurology specialists continues to rise, NeurologyLive™ keeps its audience informed with the latest clinical trial outcomes, FDA approvals, groundbreaking research, and expert opinions.

National, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#390731

United States

#163123

Health/Health Conditions and Concerns

#395

Traffic sources

Monthly visitors

Articles

FDA Grants Authorization to Epiminder’s Implantable Continuous EEG Monitor for Epilepsy Treatment

1 day ago | neurologylive.com | Isabella Ciccone

According to a new announcement, the FDA has granted De Novo authorization to Epiminder’s Minder, an implantable continuous electroencephalogram monitoring system (iCEM), marking it as the first device of its kind approved in the United States for patients with epilepsy.
Final CHAMPION MG Trial Data Show Sustained Benefit, Safety of Ravulizumab in Myasthenia Gravis

2 days ago | neurologylive.com | Isabella Ciccone

Newly published in the European Journal of Neurology, final results from the open-label extension of the phase 3 CHAMPION MG trial (NCT03920293) assessing ravulizumab (Ultomiris; AstraZeneca) revealed treatment with the agent demonstrated durable efficacy and continued safety in patients with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis (MG).1 These long-term data build on previous findings from the randomized controlled and interim open-label phases of the...
Assessing Clinical Relevancy of Visual Biomarkers in Alzheimer Disease: Alfredo A. Sadun, MD, PhD

2 days ago | neurologylive.com | Alfredo A. Sadun |Isabella Ciccone

CommentaryVideoApril 22, 2025Author(s):,Fact checked by:The chief of ophthalmology at the Doheny Eye Institute discussed decades of research uncovering how Alzheimer can impact visual function and how retinal imaging may advance diagnosis. [WATCH TIME: 13 minutes]WATCH TIME: 13 minutes"We found out that patients [with Alzheimer] do not suffer a loss of acuity nor color vision, but they do suffer losses of stereo, and most of all, contrast sensitivity and orientation.
Real-World Data Show Similar Comorbidity Rates With and Without Sodium Oxybate Treatment

3 days ago | neurologylive.com | Isabella Ciccone

Recently, Avadel Pharmaceuticals and nference announced the publication of real-world data in the Journal of Clinical Neuroscience, with results showing similar comorbidity profiles among patients with narcolepsy treated with immediate-release sodium oxybate (Xyrem) and those not treated with the drug.1,2 The retrospective analysis used de-identified electronic health records from Mayo Clinic to assess comorbidities and treatment patterns in 702 individuals with narcolepsy (treated with...
Common Idiopathic Intracranial Hypertension Drugs Show Modest Intracranial Pressure Reduction, With Noted Adverse Effects

6 days ago | neurologylive.com | Isabella Ciccone

A recently published randomized, cross-over extension trial in Headache reported that 4 drugs frequently used in idiopathic intracranial hypertension (IIH)—acetazolamide, furosemide, spironolactone, and topiramate—significantly reduced intracranial pressure (ICP) after 2 weeks of treatment, whereas amiloride did not show a significant effect.1 The analysis involved 14 women with active IIH who were treated in randomized order with the 5 different drugs over a 2-week period, separated by at...
Michael Flanagan, PhD, on Delzota’s Breakthrough Potential for Duchenne Muscular Dystrophy

1 week ago | neurologylive.com | Marco Meglio

The treatment landscape for Duchenne muscular dystrophy (DMD) is rapidly evolving, driven by advances in gene therapy, exon skipping, and steroid-sparing strategies. While corticosteroids have long served as the mainstay of care, newer therapies, like Del-zota (Avidity Biosciences), aim to more directly target the underlying defects responsible for the progressive muscle degeneration seen in DMD.
Celebrating Innovation in MS Research With the John Dystel Prize: Bruce Bebo, PhD

1 week ago | neurologylive.com | Bruce F Bebo |Isabella Ciccone

WATCH TIME: 5 minutes “I think we’ll look back—when the cures are found for MS—and we’ll see these lectures at the Academy meeting as milestones and significant jumps in our understanding of MS that led to those cures.” The John Dystel Prize for Multiple Sclerosis Research, presented by the National Multiple Sclerosis Society (the Society) in partnership with the American Academy of Neurology (AAN), honors exceptional research that has significantly advanced the understanding, prevention,...
miRNA-214 Shows Potential as Biomarker to Predict ALS Disease Progression

1 week ago | neurologylive.com | Marco Meglio

A research study published in Neurology, Neurosurgery, & Psychiatry found that microRNA (miRNA)-214, which targets the NCKAP1 gene, is linked to disease progression, severity, and survival in amyotrophic lateral sclerosis (ALS).
Expanding Access to Whole Genome Sequencing in Parkinson Research: James Beck, PhD

1 week ago | neurologylive.com | James Beck |Isabella Ciccone

WATCH TIME: 4 minutes“A key question we always get from [patients] with Parkinson is: if they don’t have a genetic form of Parkinson from a panel, do I still have Parkinson?
Migraine Treatment Zavegepant Shows No Meaningful Impact on Oral Contraceptive Exposure

1 week ago | neurologylive.com | Isabella Ciccone

In a phase 1 study published in Headache, investigators reported that multiple-dose intranasal zavegepant (Zavzpret; Pfizer), a calcitonin gene-related peptide receptor (CGRP) antagonist approved by the FDA for acute migraine treatment, did not meaningfully alter the pharmacokinetics of a single-dose oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy adult women.1 The open-label, fixed-sequence study assessed whether zavegepant would affect exposure levels of...